Nature Communications published a peer-reviewed study detailing the discovery of a covalent FGFR2-selective inhibitor designed to overcome clinically-acquired resistance mutations.
The source published the research on August 3, 2026, under the digital object identifier 10.1038/s41467-026-76339-0.
